title: [3-year follow-up after endovascular aneurysm treatment with Silk® flow diverter].
abstract: OBJECTIVE
  Flow diverters may occlude aneurysms by endoluminal reconstruction of the parent artery and by reducing the blood flow into the aneurysm. The purpose of this study was to assess the rate of intervention-associated complications and a 3-year-follow-up.
  
  
  METHODS
  We retrospectively analyzed 18 patients treated with Silk® FD. Only patients with unruptured aneurysms were included. Treatment indications were fusiform, giant or recurrent aneurysms. We considered all aneurysms to have a high likelihood of failure and/or recurrence when treated with conventional endovascular techniques.
  
  
  RESULTS
  Silk FD could directly be placed in a proper position across the whole length of the aneurysm in 16/18 patients. In one case an additional PTA was necessary. In another case the first FD could not be properly deployed. 17 of 18 aneurysms (95 %) were occluded immediately, in the mid-term follow-up after 6 months or 3 years after treatment. The overall complication rate including technical (11.1 %), acute or delayed thromboembolic complication without (11.1 %) or with (16.6 %) severe complications was documented.
  
  
  CONCLUSIONS
  FD treatment is effective with a high occlusion rate of aneurysms also in long-term follow-up. In these complex aneurysms the complication rate is higher than in conventional stent-assisted coiling.
authors: Institut für diagnostische und interventionelle Radiologie und Neuroradiologie, Universitätsklinikum Essen, Germany. adrian.ringelstein@uk-essen.de
authors: A
authors: A
authors: Ringelstein
authors: M
authors: M
authors: Schlamann
authors: S L
authors: SL
authors: Goericke
authors: C
authors: C
authors: Mönninghoff
authors: I E
authors: IE
authors: Sandalcioglu
authors: N
authors: N
authors: El Hindy
authors: M
authors: M
authors: Forsting
authors: I
authors: I
authors: Wanke
mesh_terms: D000328:Adult; D000368:Aged; D001241:Aspirin / Q000008:administration & dosage; D002533:Cerebral Angiography; D000077144:Clopidogrel; D004621:Embolization, Therapeutic; D004867:Equipment Design; D005260:Female; D006801:Humans; D002532:Intracranial Aneurysm / Q000175:diagnosis / Q000628:therapy*; D018810:Magnetic Resonance Angiography; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D011292:Premedication; D012008:Recurrence; D019233:Retreatment; D015607:Stents; D013525:Surgical Instruments; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D014057:Tomography, X-Ray Computed
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin